Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ricinoleic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.74 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.74 |
| ▸ | FABP3 | P05413 | 9/20 | 0.69 |
| ▸ | FAAH | O00519 | 3/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.62 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.56 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ricinoleic Acid SCHEMBL1091770 | 1.00 | FFAR1 (0.74) | FFAR1FFAR4FABP3FAAHNFKB1 | |
| Ricinoleic Acid SCHEMBL11598648 | 1.00 | FFAR1 (0.74) | FFAR1FFAR4FABP3FAAHNFKB1 | |
| Ricinoleic Acid SCHEMBL78693 | 1.00 | FFAR1 (0.74) | FFAR1FFAR4FABP3FAAHNFKB1 | |
| Ricinoleic Acid SCHEMBL28349268 | 1.00 | FFAR1 (0.74) | FFAR1FFAR4FABP3FAAHNFKB1 | |
| Ricinoleic Acid SCHEMBL11598640 | 1.00 | FFAR1 (0.74) | FFAR1FFAR4FABP3FAAHNFKB1 | |
| Ricinoleic Acid SCHEMBL28057112 | 1.00 | FFAR1 (0.74) | FFAR1FFAR4FABP3FAAHNFKB1 | |
| Ricinoleic Acid SCHEMBL28219680 | 0.99 | FFAR1 (0.72) | FFAR1FFAR4FABP3FAAHNFKB1 | |
| Ricinoleic Acid SCHEMBL8809771 | 0.99 | FFAR1 (0.72) | FFAR1FFAR4FABP3FAAHNFKB1 | |
| Ricinoleic Acid SCHEMBL18489805 | 0.99 | FFAR1 (0.72) | FFAR1FFAR4FABP3FAAHNFKB1 | |
| Ricinoleic Acid SCHEMBL18496848 | 0.99 | FFAR1 (0.72) | FFAR1FFAR4FABP3FAAHNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017191532-A1 | PHARMACEUTICAL FOAM COMPOSITION | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-11-09 | — | — | WO | claimed |
| EP-3844233-B1 | CRYOGENIC, KINETICALLY ACTIVE FORMULATIONS AND SYSTEMS FOR THEIR DISPENSING | FORMULATED SOLUTIONS LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| CN-116924740-B | Red mud-graphite tailing road base material and preparation method and application thereof | 济南大学 | 2025-10-31 | — | — | CN | disclosed |
| US-20250275896-A1 | WHIPPED FORMULATIONS WITH DESIRED SENSORY IMPACT | FORMULATED SOLUTIONS, LLC (US) | 2025-09-04 | — | — | US | disclosed |
| US-20250195345-A1 | WHIPPED FORMULATIONS | FORMULATED SOLUTIONS, LLC (US) | 2025-06-19 | — | — | US | disclosed |
| US-20250120886-A1 | WHIPPED FORMULATIONS | FORMULATED SOLUTIONS, LLC (US) | 2025-04-17 | — | — | US | disclosed |
| US-12161737-B2 | Whipped formulations | FORMULATED SOLUTIONS, LLC (US) | 2024-12-10 | — | — | US | disclosed |
| US-12138332-B2 | Whipped formulations | FORMULATED SOLUTIONS, LLC (US) | 2024-11-12 | — | — | US | disclosed |
| EP-3454946-B1 | WHIPPED FORMULATIONS WITH DESIRED SENSORY IMPACT | FORMULATED SOLUTIONS LLC (US) | 2024-02-28 | — | — | EP | disclosed |
| US-11826440-B2 | Thermal-stable whipped formulations | FORMULATED SOLUTIONS, LLC (US) | 2023-11-28 | — | — | US | disclosed |
| EP-1112062-B1 | MOUSSE COMPOSITION | STIEFEL RES AUSTRALIA PTY LTD (AU) | 2007-12-19 | — | — | EP | disclosed |
| US-20060292080-A1 | VITAMIN FORMULATION | CONNETICS AUSTRALIA PTY LTD (AU) | 2006-12-28 | — | — | US | disclosed |
| WO-2006129161-A2 | VITAMIN FORMULATION | STIEFEL RESEARCH AUSTRALIA PTY LTD (AU) | 2006-12-07 | — | — | WO | disclosed |
| US-20060104912-A1 | Mousse composition | CONNETICS AUSTRALIA PTY LTD (AU) | 2006-05-18 | — | — | US | disclosed |
| US-7029659-B2 | Mousse composition | CONNETICS AUSTRALIA PTY LTD. (AU) | 2006-04-18 | — | — | US | disclosed |
| US-20040184992-A1 | Mousse composition | CONNETICS AUSTRALIA PTY LTD (AU) | 2004-09-23 | — | — | US | disclosed |
| US-6730288-B1 | LOWER LEVEL OF OCCLUSIVE AGENT; GREATER DRUG SKIN PENETRATION | CONNETICS AUSTRALIA PTY LTD (AU) | 2004-05-04 | — | — | US | disclosed |
| EP-1112062-A1 | MOUSSE COMPOSITION | SOLTEC RESEARCH PTY. LTD. (AU) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000015193-A1 | MOUSSE COMPOSITION | SOLTEC RESEARCH PTY LTD (AU) | 2000-03-23 | — | — | WO | disclosed |
| US-4305936-A | SOLUBILIZERS CONSISTING OF FATTY ACID GLYCERIDES, COCAMIDOPROPYL BETAINE AND A GLYCOL | DERMIK LABORATORIES (US) | 1981-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060292080-A1 | VITAMIN FORMULATION | VDR, CYP24A1, CYP2R1 | FFAR1 407/4885FFAR4 983/4885FABP3 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.